| 1 |
34983210 | [CME/Answers: Metformin - Dos and Don'ts]. | 2022 Jan |
1 |
| 2 |
35222283 | Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma. | 2022 |
5 |
| 3 |
35337178 | Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. | 2022 Mar 21 |
1 |
| 4 |
33212505 | Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer? | 2021 Jan 1 |
6 |
| 5 |
33311577 | Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications. | 2021 May |
5 |
| 6 |
33394543 | Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. | 2021 May |
2 |
| 7 |
33889509 | Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance. | 2021 Mar |
7 |
| 8 |
34004027 | Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease? | 2021 Dec |
1 |
| 9 |
34012924 | Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma. | 2021 |
1 |
| 10 |
34149406 | Metformin Adjunct With Antineoplastic Agents for the Treatment of Lung Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies. | 2021 |
2 |
| 11 |
34875861 | [CME: Metformin - Dos and Don'ts]. | 2021 |
1 |
| 12 |
32444490 | Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. | 2020 Jun 9 |
1 |
| 13 |
32703218 | AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer. | 2020 Jul 23 |
2 |
| 14 |
32777157 | Metformin and better survival in type 2 diabetes patients with NSCLC during EGFR-TKI treatment: Implications of miR-146a? | 2020 Dec |
1 |
| 15 |
32806648 | Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. | 2020 Aug 12 |
1 |
| 16 |
33014814 | Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway. | 2020 |
6 |
| 17 |
33681180 | Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation. | 2020 |
1 |
| 18 |
30061044 | Safe Use of Metformin in Adults With Type 2 Diabetes and Chronic Kidney Disease: Lower Dosages and Sick-Day Education Are Essential. | 2019 Feb |
1 |
| 19 |
30218617 | Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients. | 2019 Mar |
1 |
| 20 |
31192264 | Association between Metformin Use and Coronary Artery Calcification in Type 2 Diabetic Patients. | 2019 |
1 |
| 21 |
31409137 | Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs. | 2019 Jan-Dec |
2 |
| 22 |
31413010 | Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. | 2019 Dec 1 |
3 |
| 23 |
31486833 | Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. | 2019 Nov 1 |
3 |
| 24 |
30154647 | Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway. | 2018 |
2 |
| 25 |
30307719 | Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling. | 2018 Dec |
1 |
| 26 |
30326091 | Metformin use was linked to hospitalization for acidosis at 6 y only in patients with eGFR < 30 mL/min/1.73 m2. | 2018 Oct 16 |
1 |
| 27 |
27981444 | Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity? | 2017 Mar |
2 |
| 28 |
28065465 | A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer. | 2017 May |
1 |
| 29 |
28391030 | Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients. | 2017 May |
3 |
| 30 |
28440424 | Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma. | 2017 Jun |
1 |
| 31 |
28526011 | Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. | 2017 May 19 |
1 |
| 32 |
28761738 | Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. | 2017 |
3 |
| 33 |
28977924 | Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function. | 2017 Sep 22 |
2 |
| 34 |
29212192 | Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction. | 2017 Nov 7 |
4 |
| 35 |
29312591 | Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib. | 2017 Dec 12 |
2 |
| 36 |
26708419 | The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. | 2016 Mar |
3 |
| 37 |
26830074 | Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study). | 2016 Mar |
1 |
| 38 |
26841718 | Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. | 2016 Feb 4 |
1 |
| 39 |
27376570 | Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. | 2016 Oct 1 |
1 |
| 40 |
28603691 | Use of cystatin C to inform metformin eligibility among adult veterans with diabetes. | 2016 Mar |
6 |
| 41 |
26341687 | Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. | 2015 Dec 1 |
5 |
| 42 |
26675396 | [Research of the influence and mechanism about metformin on the proliferation of differentiated endometrial carcinoma cells]. | 2015 Sep |
2 |
| 43 |
24322659 | Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. | 2014 Feb |
2 |
| 44 |
24644001 | Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. | 2014 May 15 |
3 |
| 45 |
24876433 | Predictors of insulin initiation in metformin and sulfonylurea users in primary care practices: the role of kidney function. | 2014 Sep |
1 |
| 46 |
25361177 | Metformin and erlotinib synergize to inhibit basal breast cancer. | 2014 Nov 15 |
2 |
| 47 |
23695170 | Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. | 2013 Jul 1 |
1 |
| 48 |
21866433 | Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. | 2011 Dec |
1 |
| 49 |
19440038 | Metformin induces unique biological and molecular responses in triple negative breast cancer cells. | 2009 Jul 1 |
2 |
| 50 |
19084933 | Metformin induces apoptosis of pancreatic cancer cells. | 2008 Dec 21 |
2 |